Singapore’s Health Sciences Authority (HSA) says a US recall of Tribenzor blood pressure medication does not affect patients in Singapore and that no changes are needed to current treatment for local users.
The recall covers Tribenzor tablets, which combine olmesartan medoxomil, amlodipine and hydrochlorothiazide, produced by Macleods Pharmaceuticals. HSA says the affected products were withdrawn from US shelves in October and are not distributed through Singapore’s local channels. The US FDA classifies the withdrawal as a Class II recall, indicating potential temporary or medically reversible health consequences and, in general, consumers are advised to continue taking the medication unless a healthcare professional instructs otherwise.
Outlet emphasis differs mainly in scope and detail. PravdaReport focuses on what the Class II designation means and points to “failed dissolution specifications” as the stated cause, relating to how the tablets break down and release active ingredients in the gastrointestinal tract. The Straits Times foregrounds the scale of the withdrawal—citing more than 3,700 bottles—while still reporting that Singapore patients are not affected, based on HSA guidance.